Form 8-K - Current report:
SEC Accession No. 0001213900-24-105072
Filing Date
2024-12-03
Accepted
2024-12-03 16:30:36
Documents
14
Period of Report
2024-11-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0223490-8k_onconetix.htm   iXBRL 8-K 26891
2 WAIVER AND AMENDMENT NO. 1 TO FORBEARANCE AGREEMENT, DATED NOVEMBER 26, 2024, BE ea022349001ex10-1_onconetix.htm EX-10.1 18149
  Complete submission text file 0001213900-24-105072.txt   226152

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE onco-20241126.xsd EX-101.SCH 3042
4 XBRL LABEL FILE onco-20241126_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE onco-20241126_pre.xml EX-101.PRE 22377
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0223490-8k_onconetix_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 241523213
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)